Skipping sentinel lymph node biopsy may be safe for some early-stage breast cancer patients
Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or survival after a median five years of follow-up, according …